From: Clinical relevance of aortic calcification in urolithiasis patients
ACI | Factors | P value | OR | 95% CI |
Age | > 65 years | 0.000 | 3.90 | 2.47-6.17 |
Sex | Male | 0.013 | 1.76 | 1.13-2.76 |
Body mass index | > 25 kg/m2 | 0.132 | 0.71 | 0.46-1.11 |
Comorbidities | Positive | 0.049 | 1.60 | 1.00-2.55 |
Lipid metabolism abnormality | Positive | 0.337 | 0.80 | 0.51-1.26 |
Serum uric acid | > 7.0 mg/dL | 0.047 | 0.52 | 0.27-0.99 |
Urine protein | > 30 mg/dL | 0.089 | 1.63 | 0.93-2.87 |
CKD stage | 3B or higher | 0.052 | 2.17 | 0.99-4.74 |
Stone formers | Positive | 0.501 | 0.85 | 0.54-1.35 |
Stage 3B CKD | Factors | P value | OR | 95% CI |
Age | > 65 years | 0.004 | 4.11 | 1.59-10.6 |
Sex | Male | 0.030 | 2.56 | 1.09-5.99 |
Body mass index | > 25 kg/m2 | 0.714 | 1.15 | 0.54-2.44 |
Comorbidities | Positive | 0.606 | 1.26 | 0.52-3.03 |
Lipid metabolism abnormality | Positive | 0.904 | 1.05 | 0.49-2.27 |
Serum uric acid | > 7.0 mg/dL | 0.001 | 4.53 | 1.94-10.6 |
Urine protein | > 30 mg/dL | 0.003 | 3.22 | 1.50-6.91 |
ACI | > 13.0% | 0.047 | 2.28 | 1.01-5.17 |
Stone formers | Positive | 0.005 | 4.00 | 1.52-10.5 |